Complications of hypertension and the role of angiotensin receptor blockers in hypertension trials

Keywords

Geography, Political science

References

• Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.Fernando Reati — 2002
• Blockade of atrial angiotensin II type 1 receptors: a novel antiarrhythmic strategy to prevent atrial fibrillation?Helmut Klein, Andreas Goette — 2003
• Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.Sarah Lewington, Robert Clarke, Nawab Qizilbash — 2002
• Are All the Hypertensives Made Equal?Arnljot Flaa, Sverre E. Kjeldsen — 2006
• Angiotensin receptor blockers do not increase risk of myocardial infarction.Ross T. Tsuyuki, Michael McDonald — 2006
• Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies.Björn Dahlöf, Kjell Pennert, Lennart Hansson — 1992
• Fibrosis and hypertensive heart diseaseKarl T. Weber — 2000
• Mechanism of Angiotensin II Type 1 Receptor Blocker Action in the Regression of Left Ventricular HypertrophySverre E. Kjeldsen, A Strand, Stevo Julius — 2006
• Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension studyLars Lindholm, Hans Ibsen, Knut Borch‐Johnsen — 2002
• Antihypertensive therapy and incidence of type 2 diabetes in an elderly cohort.Raj Padwal, Muhammad Mamdani, David A. Alter — 2004
• Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trialRoland E. Schmieder, Sverre E. Kjeldsen, Stevo Julius — 2008
• The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trialHans Lithell, Lennart Hansson, Ingmar Skoog — 2003
• Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patientsMaria Leonarda De Rosa, Piercarmine Cardace, Massimiliano Rossi — 2002
• Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.Lars Lindholm, Hans Ibsen, Björn Dahlöf — 2002
• Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular DiseaseRalph A. DeFronzo, Eleuterio Ferrannini — 1991
• Chronic Renal Diseases: Renoprotective Benefits of ReninAngiotensin System InhibitionGiuseppe Remuzzi, Piero Ruggenenti, Norberto Perico — 2002
• Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.Sverre E. Kjeldsen, B. Dahlor, Richard B. Devereux — 2002
• Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in ratsPer‐Ola Carlsson, Christian Berne, Leif Jansson — 1998
• Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI ParadoxMartin H. Strauss, Alistair S. Hall — 2006
• Combined blockade of AT1-receptors and ACE synergistically potentiates antihypertensive effects in SHRWalter Raasch, Olaf J hren, Stefan Schwartz — 2004

Cited by

• Management of hypertension in the outpatient setting.Domenic A. Sica — 2008
• Optimization of Hypertension Management: The Role of Angiotensin Receptor Blocker-Calcium Channel Blocker CombinationsGianfranco Parati — 2009
• Modifications by Olmesartan medoxomil treatment of the platelet protein profile of moderate hypertensive patientsDaniel Sacristán, María Marqués, José J. Zamorano‐León — 2008
• Down-regulation of Brain Gα12 attenuates Angiotensin II Dependent Hypertension.Juan Gao, Ian Denys, Amir Shahien — 2019

Related papers

No related papers recorded.